Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

MLA

Vittorio Fusco, et al. “Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et Al. Published on Lancet Oncology.” Dentistry Journal, vol. 6, no. 3, Sept. 2018, p. 42. EBSCOhost, https://doi.org/10.3390/dj6030042.

APA

Vittorio Fusco, Giuseppina Campisi, Paul de Boissieu, Federico Monaco, Anna Baraldi, Gianmauro Numico, & Alberto Bedogni. (2018). Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology. Dentistry Journal, 6(3), 42. https://doi.org/10.3390/dj6030042

Chicago

Vittorio Fusco, Giuseppina Campisi, Paul de Boissieu, Federico Monaco, Anna Baraldi, Gianmauro Numico, and Alberto Bedogni. 2018. “Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et Al. Published on Lancet Oncology.” Dentistry Journal 6 (3): 42. doi:10.3390/dj6030042.